cnbc.com / .cnbc-com-health-care / Page 3

The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.

While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.

UnitedHealth expects 2026 revenue to come in greater than $439 billion, which is a 2% year-over-year decline that reflects "right-sizing across the enterprise."

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.

The service uses large language models and references patients medical records to answer questions, manage medications and book appointments.

OpenEvidence, based in Massachusetts, has topped a $12 billion valuation in a funding round led by Thrive and DST.

Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating early detection of lung cancer.

Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.